Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15749273 | 0.94 | USP30 (0.54) | USP30FFAR1FAAHBACE1KDM4E | |
| SCHEMBL22776955 | 0.91 | USP30 (0.50) | USP30FFAR1FAAHKDM4EPKM | |
| SCHEMBL25209448 | 0.90 | USP30 (0.46) | USP30FFAR1FAAHGPR119 | |
| SCHEMBL25615939 | 0.90 | USP30 (0.46) | USP30FFAR1FAAHGPR119 | |
| SCHEMBL12101515 | 0.90 | FFAR1 (0.51) | USP30FFAR1BACE1 | |
| SCHEMBL30175048 | 0.88 | USP30 (0.50) | USP30FFAR1BACE1KDM1A | |
| SCHEMBL29339937 | 0.88 | USP30 (0.50) | USP30FFAR1BACE1KDM1A | |
| SCHEMBL2795787 | 0.88 | USP30 (0.50) | USP30FFAR1BACE1KDM1A | |
| SCHEMBL15379160 | 0.88 | FFAR1 (0.51) | USP30FFAR1FAAHKDM4EPKM | |
| SCHEMBL31565525 | 0.86 | FFAR1 (0.47) | USP30FFAR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-12122767-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024213125-A1 | BRM SELECTIVE DEGRADATION AGENT AND USE THEREOF | 南京再明医药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240309008-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | USP30 1156/4885FFAR1 120/4885FAAH 2825/4885 |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | USP30 4610/4885FFAR1 2898/4885FAAH 4873/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | USP30 1139/4885FFAR1 515/4885FAAH 1632/4885 |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | USP30 1940/4885FFAR1 2789/4885FAAH 4450/4885 |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | ALK, ABL2, ACVR2A | USP30 4365/4885FFAR1 2622/4885FAAH 3353/4885 |
| US-12122767-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | USP30 4106/4885FFAR1 2111/4885FAAH 2187/4885 |
| US-20240309008-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | ALK, ABL2, ACVR2A | USP30 4365/4885FFAR1 2622/4885FAAH 3353/4885 |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | NQO2, NQO1, GLS | USP30 4702/4885FFAR1 4356/4885FAAH 4478/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | USP30 1139/4885FFAR1 515/4885FAAH 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.